Related Experiment Videos
Exogenous wild-type p16INK4A gene induces delayed cell proliferation and promotes chemosensitivity through decreased
Yong-Wook Jeong1, Ki-Sung Kim, Jae-Young Oh
1Department of Microbiology, College of Medicine, Seonam University, Namwon, Chunpook 590-711, Republic of Korea.
Abstract:
Human gastric cancer SNU 484 cells express mutant p16, which migrates slower than the wild-type p16. We constructed an expression vector containing human p16 cDNA to evaluate the cytotoxic effects of exogenous p16 expression on SNU 484 cell proliferation and to explore the potential use of p16 in cancer gene therapy. The stable transfectant expressing wild-type p16, showed a 2-fold slower growth rate than mock and non-infected cells through down-regulation of CDK4-dependent kinase activity. When cells were transiently transfected with mock or p16 encoded vector, the mock cells showed larger survival colonies than those of wild-type p16. Furthermore, p16-expressing stable transfectant was readily progressed into cell death by combination with treatment of chemotherapeutic drug in a dose-dependent manner. According to western blot analysis, both decreased expression of pRB and increased expression of E2F-1 may contribute to the susceptibility of cell death. Our data indicate that exogenous wild-type p16 induces delayed cell proliferation and promotes chemo-sensitivity in the gastric cancer cell line, implying the promise of p16 in cancer gene therapy.
Insights
Exogenous wild-type p16 expression significantly slows gastric cancer cell growth and enhances sensitivity to chemotherapy. This suggests p16 holds promise for future cancer gene therapy strategies.
Area of Science:
- Molecular Biology
- Cancer Research
- Genetics
Background:
- Human gastric cancer SNU 484 cells exhibit a mutant p16 protein.
- Investigating the role of p16 in cell cycle regulation is crucial for understanding gastric cancer progression.
Purpose of the Study:
- To evaluate the cytotoxic effects of exogenous wild-type p16 expression on SNU 484 gastric cancer cells.
- To explore the potential of p16 as a therapeutic agent in cancer gene therapy.
Main Methods:
- Construction of an expression vector containing human p16 cDNA.
- Stable and transient transfection of SNU 484 cells with p16 or mock vectors.
- Cell proliferation assays, colony formation assays, and western blot analysis.
Main Results:
- Stable p16 expression resulted in a 2-fold slower growth rate by down-regulating CDK4 activity.
- p16-expressing cells exhibited reduced survival colonies compared to mock-transfected cells.
- p16 expression sensitized cells to chemotherapeutic drugs, involving decreased pRB and increased E2F-1 expression.
Conclusions:
- Exogenous wild-type p16 induces delayed cell proliferation in gastric cancer cells.
- p16 expression enhances chemo-sensitivity, indicating its potential in gastric cancer gene therapy.